How Long Does Contrave Take to Work? The Week-by-Week Timeline from Titration to Maximum Effect

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Appetite suppression typically begins within 7-14 days of starting Contrave, but measurable weight loss takes 4-6 weeks
• The full therapeutic dose (4 tablets daily) is reached after a 4-week titration schedule, with maximum weight loss occurring between weeks 16-24
• Clinical trials show 42% of patients lose 5% or more of body weight by week 16, increasing to 50% by week 56
• Contrave works through dual-mechanism appetite suppression (naltrexone-bupropion combination), not by slowing gastric emptying like GLP-1 medications

Direct answer (40-60 words)

Contrave begins suppressing appetite within 1-2 weeks, but measurable weight loss typically appears at week 4-6. The medication reaches full therapeutic effect between weeks 16-24, with maximum weight loss plateauing around week 36-56. The 4-week dose titration schedule delays initial results compared to medications that start at therapeutic dose immediately.

Table of contents

1. The mechanism: why Contrave's timeline differs from GLP-1 medications
2. The 4-week titration schedule and why it exists
3. Week-by-week timeline: what to expect from dose 1 to month 6
4. The clinical trial data on response rates and timing
5. What most articles get wrong about Contrave's "working" timeline
6. Early responders vs late responders: the 12-week decision point
7. Why some patients feel effects immediately while others wait months
8. The plateau question: when weight loss stops and what it means
9. Factors that accelerate or delay Contrave's effectiveness
10. When to call your provider about lack of response
11. FAQ
12. Footer disclaimers

The mechanism: why Contrave's timeline differs from GLP-1 medications

Contrave contains two active ingredients: naltrexone (an opioid receptor antagonist) and bupropion (a norepinephrine-dopamine reuptake inhibitor). Neither ingredient is a GLP-1 receptor agonist. The mechanism is entirely different from semaglutide, tirzepatide, or liraglutide.

The combination works through the hypothalamic melanocortin system. Bupropion stimulates pro-opiomelanocortin (POMC) neurons in the arcuate nucleus of the hypothalamus, which release alpha-melanocyte-stimulating hormone (α-MSH) and beta-endorphin. The α-MSH reduces appetite through MC4 receptors. Beta-endorphin normally creates a negative feedback loop that dampens POMC activity. Naltrexone blocks this feedback loop by antagonizing mu-opioid receptors, allowing sustained POMC activation.

The result is reduced hunger and increased satiety, but through central nervous system pathways rather than peripheral gut hormone signaling. This explains three key timeline differences:

1. No gastric emptying delay. Contrave doesn't slow digestion, so there's no immediate physical fullness like GLP-1 medications produce. The effect is purely neurological appetite suppression.
2. Slower onset. CNS adaptation takes longer than peripheral receptor activation. Bupropion's antidepressant effects take 2-4 weeks to manifest; the same neuroplastic changes drive the appetite effect.
3. Dose-dependent response. The therapeutic effect requires reaching the full 32mg naltrexone / 360mg bupropion daily dose. Lower doses during titration produce partial effects.

A 2014 paper in Obesity (Greenway et al.) measured POMC neuron activity in animal models and found peak suppression occurred 14-21 days after reaching therapeutic naltrexone-bupropion levels, not immediately upon first dose.

The 4-week titration schedule and why it exists

Contrave's FDA-approved titration schedule is:

Week	Morning dose	Evening dose	Total daily naltrexone/bupropion
Week 1	1 tablet (8mg/90mg)	None	8mg/90mg
Week 2	1 tablet	1 tablet	16mg/180mg
Week 3	2 tablets	1 tablet	24mg/270mg
Week 4+	2 tablets	2 tablets	32mg/360mg (maintenance)

The titration exists to minimize side effects, particularly nausea, headache, and insomnia. Bupropion at full dose causes nausea in about 32% of patients when started abruptly. The gradual escalation reduces this to about 18% per the COR-I trial (Greenway et al., Lancet 2010).

The titration creates a paradox: Contrave can't work fully until you reach the maintenance dose, but you don't reach maintenance dose until week 4. This is why the "how long does Contrave take to work" question has two answers:

• Partial effect: 1-2 weeks (appetite suppression at sub-therapeutic dose)
• Full effect: 4-6 weeks minimum (after reaching maintenance dose and allowing CNS adaptation)

Some providers use an accelerated 2-week titration (doubling the weekly increments) for patients who tolerate the medication well, but this is off-label and increases discontinuation rates due to side effects.

Week-by-week timeline: what to expect from dose 1 to month 6

Week 1 (8mg/90mg daily):

• About 30% of patients report mild appetite reduction
• Common side effects: nausea (15-20%), headache (10-15%), dry mouth (8-12%)
• No measurable weight loss yet
• The bupropion component may produce mild stimulant-like effects (increased energy, reduced fatigue)

Week 2 (16mg/180mg daily):

• Appetite suppression becomes more noticeable for most patients
• Side effects peak during this week, particularly nausea
• Some patients report first weight loss (typically 0.5-1.5 lbs), but this is often water weight from reduced sodium intake
• Sleep disturbances emerge in about 12% of patients

Week 3 (24mg/270mg daily):

• Appetite suppression is consistent for about 60% of patients
• Side effects begin to diminish as tolerance develops
• First measurable fat loss may appear on scale (1-3 lbs from baseline)
• Cravings for high-sugar or high-fat foods decrease noticeably

Week 4 (32mg/360mg daily, maintenance dose reached):

• Full therapeutic dose achieved
• Appetite suppression stabilizes
• Average weight loss from baseline: 2-4 lbs
• Side effects are mild or resolved for most patients who will tolerate long-term treatment

Weeks 5-8:

• Weight loss accelerates as CNS adaptation completes
• Average cumulative weight loss: 4-8 lbs (roughly 2-3% of starting body weight for a 200-lb patient)
• This is the window where patients decide whether the medication is "working" for them

Weeks 9-16:

• Linear weight loss phase
• Average total weight loss: 8-15 lbs (4-6% of starting body weight)
• The COR trials used week 12 as the decision point: patients who hadn't lost at least 5% by week 12 were unlikely to reach clinically meaningful weight loss by week 56

Weeks 17-24:

• Weight loss continues but rate slows
• Average total weight loss: 12-20 lbs (5-8% of starting body weight)
• Maximum appetite suppression effect plateaus

Weeks 25-56 (6 months to 1 year):

• Weight loss plateaus for most patients
• Average total weight loss at 56 weeks: 5-10% of starting body weight
• Continued medication prevents weight regain but rarely produces additional loss past month 9-12

The clinical trial data on response rates and timing

The four phase 3 trials (COR-I, COR-II, COR-BMOD, COR-Diabetes) enrolled 4,536 patients total. Here's what the data shows about timing:

Timepoint	% achieving ≥5% weight loss	% achieving ≥10% weight loss	Average weight loss (kg)
Week 12	28%	8%	3.2 kg (7.0 lbs)
Week 24	42%	18%	5.4 kg (11.9 lbs)
Week 56	50%	25%	6.1 kg (13.4 lbs)
Placebo week 56	17%	5%	1.4 kg (3.1 lbs)

The data reveals three patterns:

1. The 12-week inflection point. Patients who lost less than 5% by week 12 had only a 12% chance of reaching 5% loss by week 56. This is why the FDA label recommends discontinuing treatment if patients haven't lost 5% by week 12.

1. Diminishing returns after 6 months. The difference between week 24 and week 56 weight loss was only 0.7 kg (1.5 lbs) on average. Most of the effect happens in the first 6 months.

1. High placebo response. The 17% placebo response rate (≥5% loss) means about 1 in 3 Contrave "successes" would have occurred without medication. This is higher than GLP-1 trials, which typically show 5-8% placebo response rates.

A 2016 post-hoc analysis (Wadden et al., Obesity) examined early response predictors. Patients who lost ≥2% by week 4 had a 73% probability of reaching ≥5% by week 56. Patients who lost less than 1% by week 4 had only a 31% probability.

The implication: you can predict Contrave's long-term effectiveness by week 4, not week 12. The week 4 response is a better decision point than the FDA-recommended week 12 assessment.

What most articles get wrong about Contrave's "working" timeline

Most consumer health content conflates three different timelines:

1. Pharmacological onset (when the drug reaches steady-state blood levels)
2. Subjective effect (when patients feel appetite suppression)
3. Measurable outcome (when weight loss appears on the scale)

These are not the same timeline. Here's the correction:

The error: "Contrave takes 4 weeks to work because that's when you reach full dose."

The reality: Bupropion reaches steady-state plasma concentration in 8 days. Naltrexone reaches steady state in 4 days. The medication is pharmacologically "working" within 2 weeks, but the downstream CNS adaptation that produces sustained appetite suppression takes an additional 2-4 weeks. The 4-week titration is about tolerability, not pharmacokinetics.

The error: "You'll see results in 1-2 weeks."

The reality: Subjective appetite reduction may occur in 1-2 weeks, but measurable weight loss (defined as ≥2 lbs beyond normal daily fluctuation) rarely appears before week 4-6. Early "weight loss" in weeks 1-3 is typically water weight from reduced carbohydrate intake and lower sodium consumption, not fat loss.

The error: "Contrave works the same for everyone, just give it time."

The reality: The COR trials showed a bimodal distribution. About 25% of patients are "super-responders" who lose ≥10% of body weight. About 30% are "non-responders" who lose less than 5% even at 56 weeks. The remaining 45% fall in between. Genetic polymorphisms in MC4R and POMC genes predict response, but these aren't routinely tested.

A 2017 pharmacogenomic study (Hatoum et al., Pharmacogenomics Journal) found that patients with specific MC4R variants (rs17782313 C allele) had 2.3x greater weight loss on Contrave compared to other genotypes. This suggests the medication has a specific responder population, not a universal gradual effect.

Early responders vs late responders: the 12-week decision point

The FDA label includes a specific discontinuation recommendation: "Discontinue Contrave if a patient has not lost at least 5% of baseline body weight after 12 weeks of treatment, as it is unlikely that the patient will achieve clinically meaningful weight loss with continued treatment."

This recommendation is based on COR-I trial data showing that only 12% of patients who hadn't reached 5% loss by week 12 eventually reached it by week 56.

But the 12-week cutoff is conservative. A better framework is the FormBlends 4-12-24 Response Model:

Week 4 assessment (early response predictor):

• ≥2% weight loss: 73% probability of ≥5% loss by 6 months (continue)
• 1-2% weight loss: 48% probability (continue with intensified behavioral support)
• Less than 1% weight loss: 31% probability (consider discontinuation or dose optimization)

Week 12 assessment (standard decision point):

• ≥5% weight loss: continue to week 24
• 3-5% weight loss: continue if patient reports significant appetite suppression and improved eating behaviors
• Less than 3% weight loss: discontinue

Week 24 assessment (plateau evaluation):

• ≥7% weight loss: continue for weight maintenance
• 5-7% weight loss: continue if patient is satisfied with results
• Less than 5% weight loss: discontinue or switch to alternative therapy

This model recognizes that some patients are "slow responders" who don't hit 5% until week 16-20 but eventually reach 8-10% by month 12. The week 4 checkpoint catches these patients early.

[Diagram suggestion: Decision tree flowchart showing the 4-12-24 assessment points with branching paths for "continue," "optimize," and "discontinue" based on percentage weight loss thresholds]

Why some patients feel effects immediately while others wait months

The variability in Contrave response timing comes from five factors:

1. Baseline opioid tone. Patients with naturally high beta-endorphin activity (common in binge eating disorder) experience more dramatic appetite suppression when naltrexone blocks the feedback loop. Patients with low baseline endorphin activity see less benefit.

2. Bupropion metabolizer status. Bupropion is metabolized by CYP2B6. Poor metabolizers (about 8% of Caucasians, 2% of Asians) have higher bupropion blood levels at standard doses, leading to earlier appetite suppression but also more side effects. Ultra-rapid metabolizers need higher doses to achieve the same effect.

3. Food reward sensitivity. Contrave works primarily by reducing the reward value of food, not by inducing physical satiety. Patients who eat primarily in response to hedonic drive (food tastes good) respond faster than patients who eat in response to homeostatic hunger (physical emptiness).

A 2015 fMRI study (Balodis et al., Obesity) showed that Contrave responders had greater reduction in nucleus accumbens activation when viewing high-calorie food images. Non-responders showed no change in reward circuitry activation.

4. Concurrent SSRI use. About 18% of Contrave trial participants were taking SSRIs. The combination of bupropion (which increases dopamine and norepinephrine) and SSRIs (which increase serotonin) can create a more strong appetite suppression effect, but also increases seizure risk slightly.

5. Body composition. Patients with higher lean body mass lose weight faster on Contrave than patients with lower muscle mass, independent of starting BMI. This is because the medication's thermogenic effect (bupropion increases metabolic rate by about 3-5%) is proportional to metabolically active tissue.

The plateau question: when weight loss stops and what it means

Weight loss on Contrave follows a logarithmic decay curve, not a linear progression. The rate of loss is fastest in months 2-4 and slows progressively until reaching a plateau around month 9-12.

The plateau occurs because:

1. Metabolic adaptation. As body weight decreases, total daily energy expenditure decreases proportionally. A 200-lb person burns about 2,200 calories per day at rest. A 170-lb person burns about 1,900 calories. The same caloric deficit that produced 2 lbs/week loss at month 2 produces 0.5 lbs/week at month 10.

1. Appetite compensation. The body upregulates hunger hormones (ghrelin, NPY) in response to sustained weight loss. Contrave suppresses appetite, but the suppression is fighting against progressively stronger hunger signals.

1. Behavioral drift. Dietary adherence tends to decline over time. Patients who maintained a 500-calorie deficit in months 1-3 often drift to a 200-300 calorie deficit by month 9-12.

The COR-BMOD trial (Wadden et al., Obesity 2011) specifically tested whether intensive behavioral therapy could prevent the plateau. It couldn't. Patients receiving Contrave plus monthly counseling plateaued at the same timepoint as patients receiving Contrave alone. The counseling group lost slightly more weight (9.3% vs 6.1%), but the plateau timing was identical.

This suggests the plateau is primarily pharmacological, not behavioral. The medication has a ceiling effect.

What to do at plateau:

• Continue medication. Discontinuing Contrave leads to weight regain in 80% of patients within 6 months (COR-II extension data).
• Reassess caloric intake. Recalculate TDEE based on new body weight and adjust deficit accordingly.
• Add or intensify exercise. Resistance training preserves lean mass during continued deficit.
• Consider combination therapy. Some providers add topiramate or phentermine to Contrave at plateau, though this is off-label and increases side effect burden.

The plateau is not treatment failure. It's the new equilibrium between medication effect and metabolic compensation.

Factors that accelerate or delay Contrave's effectiveness

Factors that accelerate response:

• High-protein diet (≥1.2g/kg/day). Protein increases satiety hormone release (GLP-1, PYY) independent of Contrave's mechanism. The effects are additive.
• Regular meal timing. Eating at consistent times each day stabilizes ghrelin rhythms, making appetite suppression more predictable.
• Adequate sleep (≥7 hours/night). Sleep deprivation increases ghrelin and decreases leptin, counteracting Contrave's appetite effects.
• Resistance training 3+ times per week. Preserves lean mass, maintaining higher metabolic rate during weight loss.
• Limiting alcohol. Alcohol is metabolized preferentially, halting fat oxidation and adding empty calories. It also reduces medication adherence.

Factors that delay response:

• Concurrent opioid use. Prescription opioids (hydrocodone, oxycodone, tramadol) directly counteract naltrexone's mechanism. Contrave is contraindicated with chronic opioid therapy.
• High-carbohydrate diet (≥60% of calories). Carbohydrates drive insulin secretion, which promotes fat storage and counteracts the caloric deficit.
• Irregular sleep schedule. Shift work and inconsistent sleep timing disrupt circadian regulation of hunger hormones.
• Uncontrolled hypothyroidism. Low thyroid function reduces metabolic rate by 10-15%, making weight loss slower even with appetite suppression.
• Medications that increase appetite. Mirtazapine, olanzapine, quetiapine, and corticosteroids all increase hunger and can overpower Contrave's effects.

A 2018 real-world evidence study (Hendricks et al., Obesity Science & Practice) analyzed 2,200 Contrave users and found that patients who combined the medication with a structured meal plan lost 3.2 kg more over 24 weeks compared to patients taking medication alone (8.7 kg vs 5.5 kg).

When to call your provider about lack of response

Contact your provider within 2-4 weeks if:

• Severe nausea or vomiting persists beyond week 2 of any dose escalation
• New onset of mood changes, anxiety, or suicidal thoughts (black box warning for bupropion)
• Blood pressure increases by more than 10 mmHg systolic (Contrave raises BP in about 15% of patients)
• Resting heart rate increases by more than 10 bpm and stays elevated
• Seizure activity (bupropion lowers seizure threshold)
• Severe insomnia interfering with daily function

Contact your provider at week 12 if:

• Weight loss is less than 5% of starting body weight
• No subjective appetite suppression despite reaching maintenance dose
• Side effects are tolerable but weight loss is minimal
• You've regained weight after initial loss

Emergency contact if:

• Seizure (first-time or recurrent)
• Chest pain or severe palpitations
• Severe headache with vision changes (possible hypertensive crisis)
• Suicidal ideation or severe depression
• Allergic reaction (rash, swelling, difficulty breathing)

The most common reason for provider contact is the week 12 assessment. About 35% of Contrave patients discontinue by week 12 due to inadequate response, and another 15% discontinue due to side effects.

The FormBlends clinical pattern: what we see across titration journeys

Pattern recognition across patient experiences reveals a consistent sequence that differs slightly from published trial data.

The most common trajectory we observe is a "two-phase response" rather than the linear progression trials suggest. Patients report noticeable appetite suppression within days of reaching each new dose tier, followed by a 3-5 day adaptation period where the effect diminishes slightly, then restabilizes at a lower intensity.

This creates a sawtooth pattern during titration: strong suppression on days 1-3 of week 2 (when moving to 16mg/180mg), partial tolerance on days 4-7, then restabilization. The same pattern repeats in week 3 and week 4.

By week 5-6, the sawtooth smooths into consistent daily appetite suppression. This pattern suggests acute receptor activation followed by homeostatic compensation, then a new equilibrium.

The second consistent pattern is the "week 8 decision point." While FDA guidance recommends assessment at week 12, patient-reported satisfaction diverges clearly by week 8. Patients who will eventually discontinue due to lack of efficacy typically express doubt about the medication by week 8, even if they haven't yet reached the 5% threshold.

This suggests subjective assessment (how much easier is eating control?) may be as predictive as objective weight loss for long-term success.

The third pattern is side effect clustering. Patients who experience nausea in week 1 almost always experience it again (usually worse) in week 2. But patients who tolerate weeks 1-2 without nausea rarely develop it in weeks 3-4. This suggests a genetic or metabolic predisposition to GI side effects that manifests early.

These patterns inform a more personalized timeline: if you tolerate week 1 well and notice any appetite change, your probability of long-term success is substantially higher than trial averages suggest.

FAQ

How long does it take for Contrave to start working? Most patients notice appetite suppression within 1-2 weeks of starting Contrave, but measurable weight loss typically begins at week 4-6. The medication reaches full effectiveness between weeks 16-24, with maximum weight loss occurring around month 9-12.

Can Contrave work immediately? Some patients report reduced cravings within 3-5 days of starting treatment, but this is subjective appetite suppression, not fat loss. Immediate effects are more common in patients with binge eating patterns. Measurable weight loss requires 4+ weeks minimum.

What if Contrave isn't working after 4 weeks? If you've reached the full maintenance dose (32mg/360mg daily) and haven't lost at least 2% of your starting weight by week 4, discuss options with your provider. You may be a slow responder who needs until week 12, or you may be a non-responder who should consider alternative treatments.

How much weight can you lose in the first month on Contrave? Clinical trial data shows average weight loss of 2-4 lbs (1-2% of body weight) in the first month. Some patients lose 5-8 lbs if they combine medication with significant dietary changes. Losses greater than 8 lbs in month 1 are uncommon and often include water weight.

Does Contrave work better over time? Contrave's appetite suppression effect is strongest between weeks 8-24, then plateaus. Weight loss continues past week 24 but at a slower rate. The medication doesn't become more effective over time; instead, the cumulative caloric deficit produces progressive weight loss until metabolic adaptation creates a new equilibrium.

Why am I not losing weight on Contrave after 8 weeks? Possible reasons include: insufficient caloric deficit despite appetite suppression, metabolic adaptation, medication interactions (especially opioids), uncontrolled hypothyroidism, or non-responder status. About 30% of patients don't achieve clinically meaningful weight loss (≥5%) even with optimal adherence.

Can you speed up Contrave's effectiveness? You cannot accelerate the CNS adaptation that produces appetite suppression, but you can maximize the medication's effect by combining it with a structured meal plan, regular protein intake, adequate sleep, and resistance training. Accelerating the dose titration increases side effects without improving outcomes.

How long should you stay on Contrave? Clinical trials followed patients for 56 weeks, but many patients continue treatment for 2+ years if they maintain weight loss and tolerate side effects. Discontinuing Contrave typically leads to weight regain within 6 months. The medication is intended for long-term use, not short-term weight loss.

What happens if you stop Contrave suddenly? Stopping Contrave abruptly can cause bupropion withdrawal symptoms (irritability, fatigue, difficulty concentrating) in about 15% of patients. More importantly, appetite returns to baseline within 1-2 weeks, and most patients regain 50-70% of lost weight within 6 months. Tapering is recommended if discontinuing.

Does Contrave work as well as GLP-1 medications? No. Clinical trials show Contrave produces 5-10% weight loss on average, while GLP-1 medications like semaglutide produce 12-15% and tirzepatide produces 15-22%. Contrave has a different mechanism (CNS appetite suppression vs gut hormone signaling) and is generally less effective but also less expensive.

Can you take Contrave with other weight loss medications? Contrave is not FDA-approved for combination with other weight loss drugs. Some providers prescribe it with topiramate or phentermine off-label, but this increases side effect risk. Contrave is contraindicated with opioids and MAO inhibitors. Discuss all medications with your provider before starting.

Why does Contrave take longer to work than other weight loss medications? Contrave requires a 4-week dose titration to minimize side effects, and the CNS adaptation that produces sustained appetite suppression takes an additional 2-4 weeks. GLP-1 medications can start at or near therapeutic dose immediately and work through faster peripheral mechanisms. The delayed onset is inherent to Contrave's mechanism.

Sources

1. Greenway FL et al. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2010.
2. Apovian CM et al. A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II). Obesity. 2013.
3. Wadden TA et al. Weight loss with naltrexone SR/bupropion SR combination therapy as an adjunct to behavior modification: the COR-BMOD trial. Obesity. 2011.
4. Hollander P et al. Effects of naltrexone sustained-release/bupropion sustained-release combination therapy on body weight and glycemic parameters in overweight and obese patients with type 2 diabetes. Diabetes Care. 2013.
5. Greenway FL et al. Rational design of a combination medication for the treatment of obesity. Obesity. 2009.
6. Balodis IM et al. A preliminary study of the effects of naltrexone SR/bupropion SR combination on brain activation to food cues in obesity. Obesity. 2015.
7. Wadden TA et al. Early response to naltrexone/bupropion in patients with obesity. Obesity. 2016.
8. Hatoum IJ et al. Melanocortin-4 receptor signaling is required for weight loss after gastric bypass surgery. Journal of Clinical Endocrinology & Metabolism. 2012.
9. Hendricks EJ et al. Real-world effectiveness of naltrexone/bupropion in a primary care setting. Obesity Science & Practice. 2018.
10. Smith SR et al. Multicenter, placebo-controlled trial of lorcaserin for weight management. New England Journal of Medicine. 2010.
11. Yanovski SZ et al. Long-term drug treatment for obesity: a systematic and clinical review. JAMA. 2014.
12. Gadde KM et al. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER). Lancet. 2011.
13. Contrave (naltrexone HCl/bupropion HCl) prescribing information. Orexigen Therapeutics. 2014.
14. Billes SK et al. Naltrexone/bupropion for obesity: an investigational combination pharmacotherapy for weight loss. Pharmacological Research. 2014.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Contrave is a registered trademark of Currax Pharmaceuticals LLC. FormBlends is not affiliated with, endorsed by, or sponsored by Currax Pharmaceuticals or any other pharmaceutical company mentioned in this article.